The New England journal of medicine, 2021-07, Vol.385 (3), p.228-238
2021
Details
- Autor(en) / Beteiligte
- Titel
- Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
- Ist Teil von
- The New England journal of medicine, 2021-07, Vol.385 (3), p.228-238
- Ort / Verlag
- Boston: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Link zum Volltext
- Quelle
- Alma/SFX Local Collection
- Beschreibungen/Notizen
- Standard treatment for GVHD is glucocorticoids, but for glucocorticoid-refractory GVHD, no intervention has emerged as standard second-line treatment. This trial with 329 patients compared ruxolitinib with control (chosen from among 10 possible therapies) in patients with glucocorticoid-refractory chronic GVHD. Response at week 24 was 50% with ruxolitinib as compared with 26% with control therapy.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2033122Titel-ID: cdi_proquest_miscellaneous_2552062198
- Format
- –
- Schlagworte
- Adverse events, Anemia, Bone marrow, Bone Marrow Transplantation, Chronic diseases, Committees, Corticosteroids, Cytomegalovirus, Design, Dosage, Drug therapy, Generalized linear models, Glucocorticoids, Graft versus host disease, Graft versus host reaction, Health aspects, Hematology, Janus kinase, Janus kinase 2, Leukemia, Lymphoma, Oncology, Patient outcomes, Statistical analysis, Stem cell transplantation, Thrombocytopenia, Treatments in Oncology